Alla studier
RekryteringFAS2INTERVENTIONELL

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

This study is looking at a new medicine called NS-089/NCNP-02 for boys aged 4 to 14 who have Duchenne muscular dystrophy (DMD). Specifically, it's for boys whose DMD is caused by a genetic change that can be treated by something called 'exon 44 skipping'. The study aims to find out if this new medicine is safe and how well it works. Participants will receive the medicine through a drip (IV infusion) once a week. The study is divided into two parts, with a small group of boys in the first part, and then more boys joining in the second part to gather more information. All participants will be able to walk without help.

Överblick

Status
Rekrytering
Fas
FAS2
Sponsor
NS Pharma, Inc.
Inskrivningsmål
20
Starta
22 feb 2024
Beräknad slutförande
11 Sep 2026

Vad handlar denna studie om?

Duchenne muscular dystrophy (DMD) is a serious genetic condition that causes muscles to become weaker over time. This study is testing a new medicine called NS-089/NCNP-02. The goal of this medicine is to help correct a specific genetic problem in some boys with DMD, which involves 'skipping' a part of their gene called exon 44. By doing this, the hope is to help the body make a more functional dystrophin protein, which is vital for healthy muscles.

This is a 'Phase 2' study, meaning researchers are looking closely at how safe the medicine is and starting to see if it has a positive effect. It's also 'open-label', which means both the patients and the doctors will know they are receiving the study medicine. The medicine will be given to boys aged 4 to 14 who can still walk on their own.

The study is important because it could potentially offer a new treatment option for boys with DMD who have this specific genetic change. Finding effective treatments is a crucial step towards improving the lives of individuals living with this challenging condition.

Viktiga punkter

  • This study is testing an experimental medicine (NS-089/NCNP-02) for DMD.
  • It's for boys aged 4-14 with a specific genetic change (exon 44 skipping) who can walk unassisted.
  • The medicine is given weekly through a drip.
  • The study aims to understand the medicine's safety and effectiveness.
  • Participation involves regular hospital visits for assessments and treatment.

Vem kan vara berättigad?

To join this study, boys must be between 4 and 14 years old. They need to have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) caused by a specific genetic change (mutation) that can be treated by 'exon 44 skipping'. It's also important that they can walk by themselves without any walking aids and can complete a specific walking test quickly.

Participants must have been on a steady dose of steroid medication for at least three months before starting the study and expect to continue that dose throughout. There are also some reasons why someone might not be able to join. For example, if they have certain heart problems, have used particular medications or other experimental treatments recently, or have had surgery in the last three months.

They also can't have participated in a previous study of this exact medicine (NS-089/NCNP-02) or received other similar 'exon skipping' treatments in the past year. There are other criteria too, so the study team will check everything carefully.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Is the boy between 4 and 14 years old?
  2. Does he have Duchenne muscular dystrophy with an 'exon 44 skipping' genetic change?
  3. Can he walk on his own without any walking aids?
  4. Has he been on a stable dose of steroid medication for at least 3 months?
  5. Has he avoided certain other medications or experimental treatments recently?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, the study involves weekly visits to receive the medicine, NS-089/NCNP-02, through a drip into a vein (IV infusion). The total duration of your involvement will depend on which part of the study you join.

Before treatment starts, there will be screening visits to ensure you meet all the requirements. During the study, you'll have regular check-ups, assessments of your muscle strength and movement (like walking tests), and possibly blood tests to see how the medicine is affecting you. All these visits and tests are designed to monitor your health and how the medicine is working. The study is divided into two parts, so some participants will be involved for longer than others.

Potentiella risker och fördelar

Participating in a clinical trial may offer potential benefits, such as access to a new treatment that isn't widely available. However, there are also potential risks, as the medicine is still being studied, and not all side effects or benefits are fully known. You might experience side effects, some of which could be unexpected. It's important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (25)

  • Barnsjukhuset Colorado
    Verifierat postnummer
    Aurora, USA· Rekrytering
  • Rare Disease Research, LLC - FL
    Verifierat postnummer
    Kissimmee, United States· Rekrytering
  • Rare Disease Research
    Verifierat postnummer
    Atlanta, USA· Rekrytering
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Verifierat postnummer
    Chicago, USA· Rekrytering
  • University of Kansas Medical Center (KUMC)
    Verifierat postnummer
    Kansas City, USA· Rekrytering
  • Cincinnati Barnsjukhus Medicinska Center
    Verifierat postnummer
    Cincinnati, USA· Rekrytering
  • Barnsjukhuset i Philadelphia (CHOP)
    Verifierat postnummer
    Philadelphia, USA· Rekrytering
  • University of Pittsburgh School of Medicine
    Verifierat postnummer
    Pittsburgh, USA· Rekrytering
  • UT Southwestern/Children's Health
    Verifierat postnummer
    Dallas, USA· Rekrytering
  • Virginia Commonwealth University Health System
    Verifierat postnummer
    Richmond, USA· Rekrytering
  • Perth Children's Hospital
    Verifierat postnummer
    Nedlands, Australien· Rekryterar inte ännu
  • Alberta Children's Hospital
    Verifierat postnummer
    Calgary, Kanada· Rekryterar inte ännu

Vanliga frågor

What is Duchenne muscular dystrophy (DMD)?

DMD is a genetic condition that causes muscles to get weaker over time, making it harder to move around.

What does 'exon 44 skipping' mean?

It's a way the new medicine tries to fix a specific error in the DNA of some boys with DMD, helping their bodies make a vital muscle protein.

Hur kommer medicinen att ges?

The medicine, NS-089/NCNP-02, will be given through a drip into a vein (an IV infusion) once a week.

Can I join if I use a wheelchair?

No, this study is specifically for boys who can still walk independently without any help.

Vad är en 'Fas 2'-studie?

Phase 2 studies are designed to see if a new medicine is safe and starts to show a positive effect, building on earlier safety tests.

Hur du får reda på mer

Trial info

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy …" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.